Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: A Analysis of the immunohistochemical pathological reports for HER2 of 13 CRC patients in Jiangsu Provincial Hospital. B Western blot analysis of HER2 expression in murine and human CRC cell lines. C Expression and localization of HER2 detected by immunofluorescence on MC38 HER2 , MC38 Ctrl , CT26 HER2 , and CT26 Ctrl cells. D The mRNA expression of HER2 was measured by qPCR. ** P < 0.01. E The expressions of HER2 on the cell membrane were detected using flow cytometry. F The expression and localization of HER2 in HCT116 and HT29 cells were determined by immunofluorescence. Scale bars, 10 μm.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: Immunohistochemical staining, Western Blot, Expressing, Immunofluorescence, Membrane, Flow Cytometry

Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: A In vitro growth inhibition assay for HCT116 cells treated with MMAE and Paclitaxel for 24 h. B In vitro growth inhibition assay for HCT116 and HT29 cells. C In vitro growth inhibition assay for MC38 HER2 and MC38 Ctrl cells treated with RC48 for 48 h. D In vitro growth inhibition assay for MC38 Ctrl and MC38 HER2 cells treated with MMAE for 24 h. E Flow cytometry analysis of cell cycle after treatment with different concentrations of RC48 for 48 h. F Clonogenic assay of HCT116, CT26 HER2 and MC38 HER2 treated with RC48. Data represent the mean ± SEM of three replicates. * P < 0.05, ** P < 0.01, versus as indicated. n.s. not significant.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: In Vitro, Growth Inhibition Assay, Flow Cytometry, Clonogenic Assay

Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: A MC38 Ctrl cells were treated with different concentrations of Disitamab (0, 10, 30, 100 μg/ml) for 48 h, and the expression of p-TBK1, p-IRF3, TBK1, IRF3 protein was detected by immunoblotting. B MC38 HER2 and MC38 Ctrl cells were treated with 100 μg/ml RC48 for 48 h and 30 μM CPT11 for 12 h and the expression of p-TBK1, p-IRF3, TBK1, IRF3 protein was detected by immunoblotting. C HCT116 was treated with 100 μg/ml RC48 for 48 h and 30 μM CPT11 for 12 h. D The expressions of HER2 on the cell membrane were detected using flow cytometry. MFI Mean fluorescence intensity. E Co-immunoprecipitation of endogenous HER2 and STING in HCT116. F The expression and localization of HER2 in MC38 HER2 were detected by immunofluorescence. * P < 0.05, ** P < 0.01 versus as indicated. n.s. not significant. Scale bar, 10 μm.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: Expressing, Western Blot, Membrane, Flow Cytometry, Fluorescence, Immunoprecipitation, Immunofluorescence

Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: A – E MC38 HER2 (1 × 10 6 ) cells were inoculated in the C57BL/6 mice. Drugs were given as described in Materials and Methods. B , C Tumor volume and body weight were measured every two days. D , E Solid tumors were separated and weighed after the mice were sacrificed. The data represent the mean ± SEM of 10 mice per group. F Paraffin sections of tumor tissues were analyzed by H&E staining, PCNA immunohistochemistry staining, and TUNEL fluorescent staining. G The survival of tumor-bearing mice. H – M Same experiment with CT26 HER2 in BALB/c mice. The data represent the mean ± SEM of 7 mice per group. * P < 0.05, ** P < 0.01 versus as indicated. n.s. not significant. Scale bar, 50 μm.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: Staining, Immunohistochemistry, TUNEL Assay

Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: A Immunofluorescence staining for p-TBK1 and p-IRF3 in tumor tissue in C57BL/6. B , C Immunohistochemical detection of IFN-β secretion in tumor tissue in BALB/c and C57BL/6. D LDH release assay was performed using Tils achieved from the syngeneic model of CT26 HER2 as described in material and methods. E , F Examination of CD3 + , CD8 + , IFN-γ secretion in the tumor by flow cytometry in BALB/c and C57BL/6. * P < 0.05, ** P < 0.01 versus as indicated. n.s. not significant. Scale bar, 100 μm.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Lactate Dehydrogenase Assay, Flow Cytometry

Journal: Cell Death & Disease

Article Title: A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway

doi: 10.1038/s41419-023-06073-8

Figure Lengend Snippet: RC48 exhibits the capability to bind to HER2 receptors and undergo internalization, subsequently releasing the toxin MMAE. MMAE inhibits tubulin, leading to the disruption of the cell cycle and resulting in the efficient elimination of tumor cells. Moreover, through its interaction with HER2, RC48 can alleviate the inhibition induced by internalized HER2 on the STING pathway and its downstream signaling. These combined mechanisms enable RC48 to effectively impede the proliferation of HER2-positive tumors while also enhancing their sensitivity to immunotherapy.

Article Snippet: Anti-HER2 antibody (ab134182) was from Abcam plc.

Techniques: Disruption, Inhibition

Journal: iScience

Article Title: From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies

doi: 10.1016/j.isci.2026.114907

Figure Lengend Snippet: Functional characterization of NK cells (A) Degranulation capacity of NK cells following a 2 h co-culture with K562 leukemia cells, measured by surface CD107a expression ( n = 5). (B and C) Europium-based cytotoxicity assay assessing the specific lysis of K562 target cells at E:T ratios of 10:1, 5:1, 3:1, 1:1, and 0.5:1 on day 7 (B) and day 14 (C) of culture to monitor functional decline over time ( n = 6 for both time points). Here, all comparisons were not significant and are summarized as such (n.s.: p > 0.05). (D) IFN-γ release following 16 h of co-culture of NK cells with K562 cells, quantified via Luminex assay ( n = 5). (E) Kinetic live-cell killing assay using the Incucyte monitoring of Nuclight Red signal loss in K562 cells over 72 h at an E:T ratio of 1:1 ( n = 6). (F) Proportion of donors reaching 25%, 50%, and 75% cumulative lysis thresholds during Incucyte co-culture with K562 cells. (G) CD107a degranulation assay of NK cells with or without pre-incubation with trastuzumab (anti-HER2 antibody) during a 2 h co-culture with MDA-MB-453 cells ( n = 5). (H) Incucyte-based cytotoxicity assay shows the real-time lysis of MDA-MB-453 cells by trastuzumab-loaded NK cells at an E:T ratio of 1:1 over 72 h ( n = 6). (I) Proportion of donors reaching 25%, 50%, and 75% cumulative lysis during the ADCC assay. (n varies as not all samples reached the benchmark values within the observation period). All ADCC experiments have been performed after 14 days of in vitro NK cell expansion. N/A indicates that statistical analysis was not possible for this group. 9J) CD107a degranulation of unmodified NK cells and ErbB2-CAR-NK cells after 2 h co-culture with MDA-MB-453 cells ( n = 5). (K) Incucyte-based cytotoxicity assay showing killing dynamics of ErbB2-CAR-NK cells against MDA-MB-453 cells at an E:T ratio of 1:1 over 72 h ( n = 6). (L) Proportion of donors reaching 25%, 50%, and 75% cumulative lysis during the CAR-mediated cytotoxicity assay. (n varies as not all samples reached the benchmark values within the observation period). All CAR-killing experiments have been performed after 14 days of in vitro NK cell expansion. Unless otherwise stated, n refers to biologically independent donor samples and is indicated per group. Data are shown as mean ± SEM. p-values were determined by Student’s t test with Welsh correction (A, D, F, G, I, J, and L) or by one-way ANOVA (B and C) with Tukey post-test (K and L).

Article Snippet: Mouse Monoclonal anti-CD340 (Her2) , Miltenyi Biotec , Cat# 130-124-474.

Techniques: Functional Assay, Co-Culture Assay, Expressing, Cytotoxicity Assay, Lysis, Luminex, Degranulation Assay, Incubation, ADCC Assay, In Vitro

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs enhance the cell round-up effect of Herceptin particularly under the hypoxic conditions. (A) The Herceptin-sensitive (BT474) and Herceptin-resistant cells (R20) were grown under the normoxic (normoxia) or hypoxic (hypoxia) conditions. At sub-confluent density, the cells were treated with saline (Mock), Herceptin (5 μg/ml), cerium oxide nanoparticles (CONPs) (75 μM) or Herceptin in combination with CONPs (H + C) for 24 hours prior to phase contrast microscopy. (B) Cells were analyzed for viability by separately collecting and staining the adherent and round up cells with trypan blue as described in Materials and Methods. The number inside each image in (A) indicates percentage of cells that became rounded up. *P<0.05, **P<0.01 and ***P<0.001 compared to respective mock-treated group.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Saline, Microscopy, Staining

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs sensitizes both Herceptin-sensitive and Herceptin-resistant cells to the inhibitory effect of Herceptin on cell survival and proliferative capacities more potently under hypoxia than under normoxia. The cells were grown and treated as described in Figure 1. The cells were then prepared for analysis of colony-forming capability by clonogenic assay (A) and proliferative capacity by WST-1 assay (B) as detailed in Materials and Methods. *P<0.05, **P<0.01 and ***P<0.001 compared to respective mock-treated group.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Clonogenic Assay, WST-1 Assay

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs potently and rapidly inhibit HIF-1α induction by hypoxia particularly in the Herceptin-resistant cells. A. Time-course change in HIF-1α expression under the hypoxic conditions. After incubated for indicated periods, the cells were processed for western blotting. HIF-1α levels relative to β-actin were quantified and normalized to 4-h-treated Herceptin-sensitive cells. *P<0.05 compared to columns 7 or 8. ***P<0.001 compared to column 1 as well as columns 7-10. B. CONPs markedly inhibit HIF-1α induction by hypoxia in the cells. Indicated cells were incubated either under that normoxic conditions and mock-treated only (basal) or under the hypoxic conditions and treated with vehicle (Mock), Herceptin, CONPs or their combination (H + C) for 4 hours. The cells were then processed for western blotting and quantitative analysis. *P<0.05 compared to column 7 or 8. **P<0.01 compared to column 7 or 8. ***P<0.001 compared to columns 2-4.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Expressing, Incubation, Western Blot

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: Treatment with CONPs causes slow reduction in intracellular levels of VEGF under the hypoxic conditions. A. Levels of VEGF and CAIX proteins were not affected within 8 hour treatment with Herceptin and/or CONPs. Indicated cells were incubated either under the normoxic conditions and mock-treated only (basal) or under the hypoxic conditions and treated with vehicle (Mock), Herceptin, CONPs or their combination (H + C) for 4 or 8 hours. The whole cell extracts were then processed for western blotting. B. Treatment with CONPs alone or in combination with Herceptin leads to severe decrease in levels of VEGF protein particularly in the Herceptin-resistant cells after 24 hour treatment. The cells were treated similarly as described above in A for 24 hours prior to western analysis. *1P<0.01 compared to column 1; *2P<0.01 compared to column 2; *3P<0.001 compared to column 1; *4P<0.05 compared to column 6; *5P<0.05 or 0.01 compared to column 6 or 7; *6P<0.01 or 0.001 compared to column 6 or 7. C. Levels of VEGF mRNA were not affected within 8 hours treatment with Herceptin and/or CONPs. VEGF mRNA was analyzed by semi-quantitative PCR shown here and quantitative real-time PCR (not shown).

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Incubation, Western Blot, Real-time Polymerase Chain Reaction

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: Treatment with CONPs causes rapid and significant decrease in extracellular VEGF levels under hypoxic conditions. (A-D) Dot blotting analysis of VEGF protein in the culture media of the cells. Cells were incubated either under the normoxic conditions and mock-treated (basal) or under the hypoxic conditions and treated with vehicle (Mock), Herceptin, CONPs or their combination (H + C) for 4 hours. The medium of the cells was then collected and processed for dot blotting (A, C) and quantitative (B, D) analysis of extracellular VEGF levels. *P<0.05 and **P<0.01 compared to column 2. (E) ELISA analysis of VEGF protein in the media of the cells. The cells were incubated under either the normoxic or hypoxic conditions for 24 hours. The media of these cells were then collected and processed for ELISA analysis. *1P<0.01 compared to column 1; *2P<0.01 compared to column 1’; *3P<0.05 and *4P<0.01 compared to column 5’.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Incubation, Enzyme-linked Immunosorbent Assay

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs sensitize Herceptin-resistant cells to the inhibitory effect of Herceptin on primary tumor growth. The HR20-nGL breast cancer cells were injected into the mammary fat pad of 4-6-week-old female NSG mice. The next day mice were randomly grouped into four groups and received intraperitoneal injection of 100 μl saline solution of Herceptin (2 mg/kg) in combination with CONPs (0.1 mg/kg), Herceptin, CONPs or saline alone, twice a week for two consecutive weeks. Primary tumor progression was monitored and examined by weekly BLI analysis for 8 weeks (A, B). After sectioned, the tumors were measured for weight and volume (C, D), and the tissues were further processed for IHC staining for expression of the proliferative marker Ki67 (E, F). P<0.05 compared between *H + C and saline alone, #H + C and CONPs alone, and $H + C and Herceptin alone.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Injection, Saline, Immunohistochemistry, Expressing, Marker

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs sensitize Herceptin-resistant cells to the inhibitory effect of Herceptin on tumor angiogenesis and survival. The tumor tissues collected from the mice described in Figure 6 were processed for IHC staining for expression of the angiogenic factor protein VEGF (A), the vascular endothelial marker protein CD31 (B), and the apoptotic marker protein cleaved caspase-3 (C). Optical density (OD) for expression quantification was obtained by ImageJ Fiji color deconvolution analysis and normalized to the Saline group value. *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques: Immunohistochemistry, Expressing, Marker, Saline

Journal: American Journal of Cancer Research

Article Title: Sensitization of breast cancer to Herceptin by redox active nanoparticles

doi:

Figure Lengend Snippet: CONPs sensitize the Herceptin-resistant breast cancer cells to the inhibitory effect of Herceptin on the lung metastasis. During tissue collection from the mice described in Figure 6, the lung specific BLI was performed (A) and bioluminescent intensity for the lung metastasis quantified (B). *P<0.05.

Article Snippet: Herceptin was purchased from Bio-Rad (MCA6092. a.k.a.

Techniques:

Journal: Scientific Reports

Article Title: HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior

doi: 10.1038/s41598-021-93807-3

Figure Lengend Snippet: Mass cytometry antibody panel for lung adenocarcinoma.

Article Snippet: HER2 , 148Nd , Surface , 29D8 , Fluidigm , 3148011A.

Techniques: Mass Cytometry

Journal: Journal of Nuclear Medicine

Article Title: Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

doi: 10.2967/jnumed.118.214684

Figure Lengend Snippet: NCI SBIR–Funded TRT Contracts for 2015

Article Snippet: 2016 , Rockland Immunochemicals, Inc. , Phase I , HER2-positive cancers , 68 Ga and 177 Lu , HER2 and digoxigenin , Phase I: Develop bispecific recombinant single-domain antibodies with one arm targeting cancer biomarker HER2 and another arm against digoxigenin; investigate in vivo clearance, tumor accumulation, stability, and ability to capture digoxigenylated fluorescence dyes and radionuclides.

Techniques: In Vitro, In Vivo, Marker, Fluorescence, Drug discovery, Imaging

Journal: Journal of Nuclear Medicine

Article Title: Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

doi: 10.2967/jnumed.118.214684

Figure Lengend Snippet: NCI SBIR–Funded TRT Contracts from 2016 to 2017

Article Snippet: 2016 , Rockland Immunochemicals, Inc. , Phase I , HER2-positive cancers , 68 Ga and 177 Lu , HER2 and digoxigenin , Phase I: Develop bispecific recombinant single-domain antibodies with one arm targeting cancer biomarker HER2 and another arm against digoxigenin; investigate in vivo clearance, tumor accumulation, stability, and ability to capture digoxigenylated fluorescence dyes and radionuclides.

Techniques: Radioactivity, Drug discovery, Recombinant, Biomarker Discovery, In Vivo, Fluorescence, Binding Assay, Labeling, In Vitro, Produced, Software

Journal: ACS Measurement Science Au

Article Title: Prototype Smartphone-Based Device for Flow Cytometry with Immunolabeling via Supra-nanoparticle Assemblies of Quantum Dots

doi: 10.1021/acsmeasuresciau.1c00033

Figure Lengend Snippet: Counting of SK-BR3 cells, stained with DAPI (cell nuclei) and immunolabeled with SiO 2 @(QD635-Dex)-(anti-HER2 TAC). (A) SK-BR3 cells only: (i–v) frames from smartphone FC videos of different concentrations of suspended cells. For the most dilute suspension, the arrow indicates a single cell. An intensity profile across selected cells can be found in Figure S13 . The image in (i) is a zoomed section of (v) with one (of several) SK-BR3 cells circled. Correlation plots (vi) of HER2-positive SK-BR3 cell counts derived from the smartphone FC versus a commercial cell counter. The diagonal line has a slope of unity. (B) Target SK-BR3 cells and background MDA-MB-231 cells: (i–v) frames from smartphone FC videos of mixed suspensions of SK-BR3 cells (variable amount) and MDA-MB-231 cells (approximately constant amount; DAPI stained). An intensity profile across selected cells of each type can be found in Figure S13 . Video S3 is a 10 s clip from one of the smartphone FC videos. The image in (i) is a zoomed section of (v) with one example each of a SK-BR3 cell and a MDA-MB-231 cell circled. Correlation plots of cell counts (vi) measured with a smartphone FC versus a commercial cell counter. Frame image brightness has been digitally increased for display purposes.

Article Snippet: Anti-HER2 antibody was from Novus Biologicals (Centennial, CO).

Techniques: Staining, Immunolabeling, Suspension, Derivative Assay

Journal: ACS Measurement Science Au

Article Title: Prototype Smartphone-Based Device for Flow Cytometry with Immunolabeling via Supra-nanoparticle Assemblies of Quantum Dots

doi: 10.1021/acsmeasuresciau.1c00033

Figure Lengend Snippet: Assessment of multiple colors of QDs. (A) PL emission spectra of QD490, QD540, QD585, QD605, QD635, and QD650 (solid lines). The approximate RGB color filter transmission spectra for the smartphone are overlaid (dashed lines; data courtesy of Olivier Burggraaff ). (B) Frames from smartphone FC videos showing SK-BR3 cells immunolabeled with SiO 2 @(QDλ-CM-Dex)-(anti-HER2) for QD540, QD585, QD605, or QD650. Frame image brightness has been digitally increased for display purposes. Intensity profiles across selected cells of each color of QD can be found in Figure S16 . (C) Plots of the G/B and R/B intensity ratios for individual SK-BR3 cells labeled with these four colors of SiO 2 @(QDλ-CM-Dex)-(anti-HER2). (D) Plots of the R, G, and B channel intensity values for individual SK-BR3 cells nonspecifically labeled with GSH-QD490, GSH-QD540, or GSH-QD635 (none as a SiO 2 @QD assembly).

Article Snippet: Anti-HER2 antibody was from Novus Biologicals (Centennial, CO).

Techniques: Transmission Assay, Immunolabeling, Labeling

Journal: ACS Measurement Science Au

Article Title: Prototype Smartphone-Based Device for Flow Cytometry with Immunolabeling via Supra-nanoparticle Assemblies of Quantum Dots

doi: 10.1021/acsmeasuresciau.1c00033

Figure Lengend Snippet: Counting of SK-BR3 and MDA-MB-231 cells in parallel using SiO 2 @(QD540-CM-Dex)-(anti-HER2) and SiO 2 @(QD650-CM-Dex)-(anti-MUC1), respectively. (A) Cartoon schematic of the experiment (not drawn to scale). (B) Example of a frame from a smartphone FC video. Frame image brightness has been digitally increased for display purposes. An intensity profile across selected cells of each type can be found in Figure S17 . Video S4 is a 20 s clip from one of the smartphone FC videos. (C) Examples of normalized G/B and R/B intensity ratios and cell classifications for five samples with an increasing number of MDA-MB-231 cells and an approximately constant number of SK-BR3 cells (see Figure S18 for additional data sets). Normalization of intensity ratios assisted with application of the SVM training set to the experimental data (see the SI for details). (D) Correlation plots for the measured and expected numbers of SK-BR3 and MDA-MB-231 cells, and for the measured and expected ratios of MDA-MB-231 and SK-BR3 cells. This plot includes the samples in panel (C) and in Figure S18 .

Article Snippet: Anti-HER2 antibody was from Novus Biologicals (Centennial, CO).

Techniques:

Journal: ACS Measurement Science Au

Article Title: Prototype Smartphone-Based Device for Flow Cytometry with Immunolabeling via Supra-nanoparticle Assemblies of Quantum Dots

doi: 10.1021/acsmeasuresciau.1c00033

Figure Lengend Snippet: Identification of selected breast cancer cell types (SK-BR3, MDA-MB-231, and MCF-7) using SiO 2 @(QD540-CM-Dex)-(anti-HER2), SiO 2 @(QD585-CM-Dex)-(anti-MUC1), and SiO 2 @(QD650-CM-Dex)-(anti-ER). (A) Cartoon schematic of the experiment (not drawn to scale). (B) Examples of G/B and R/B intensity ratios for a control sample without cells and suspensions of each cell type. The shaded region in the plots corresponds to the mean of the control sample data points plus four standard deviations along each intensity ratio axis. The circled regions highlight the dominant vertical, diagonal, and horizontal spread of cell counts for SK-BR3, MDA-MB-231, and MCF-7 cells, respectively.

Article Snippet: Anti-HER2 antibody was from Novus Biologicals (Centennial, CO).

Techniques: Control

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Inhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice

doi: 10.1155/2015/630760

Figure Lengend Snippet: Effect of flavonoids and scutebarbatines in SB on the levels of immune factors in Lewis tumor-bearing mice. All data were expressed as means ± SD ( n = 9).

Article Snippet: Antibodies to these immunoregulatory factors including IL-10, IL-17, FOXP3, IFN- γ , IL-2, ROR γ t, TGF- β 1, IL-6, and β -actin were obtained from Wuhan BOSTER Biological Engineering Co., Ltd. (Wuhan, China).

Techniques:

Journal: International Journal of Oncology

Article Title: Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer

doi: 10.3892/ijo.2020.4987

Figure Lengend Snippet: Establishment of TAM-resistant breast cancer cells. (A) TAM-resistant cells exhibited a more elongated, spindle-shaped morphology compared with the respective parental cells. Magnification, ×200. (B) Survival of TAM-resistant cells and the respective parental cells was evaluated using a Cell Counting kit-8 assay following treatment with various concentrations of TAM for 24 h. (C) Western blot analysis (D) and densitometry analysis of ERα and HER2 expression in MCF-7, MCF-7R, T47D and T47DR cells. Data are presented as the means ± standard deviation of the mean of 3 repeats. * P<0.05, ** P<0.01, ***P<0.001 vs. respective parental cells. TAM, tamoxifen.

Article Snippet: Non-specific binding sites were blocked by incubating the membranes with 5% non-fat milk, after which the membranes were incubated overnight at 4°C with the primary antibodies: ERα (1:1,000); HER2 (1:1,000); AKT (1:1,000); p-AKT (1:1,000); c-MYC (1:1,000); cyclin D1 (1:1,000); vimentin (1:1,000); E-cadherin (1:1,000); p21 (1:500); β-catenin (1:500); GAPDH (1:1,000) Membranes were subsequently incubated with a horseradish peroxidase-conjugated anti-rabbit/mouse immunoglobulin G secondary antibody (1:1,000; cat. no. BA1075 and BA1051; Wuhan Boster Biological Technology, Ltd.).

Techniques: Cell Counting, Western Blot, Expressing, Standard Deviation